JOAN BRUNET VIDAL

Projectes

Oncología de Precisión de Girona

Evaluación de un nuevo biomarcador pan-cáncer para mejorar la predicción de respuesta a inmunoterapia.

Codi oficial: biomarcador pan-cáncer Data inicio:19/10/2020 Data fi: 01/12/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA (SEOM)

Oncología de Precisión de Girona

Data-driven cancer genome interpretation for personalised cancer treatment

Codi oficial: 101057509 Data inicio:01/11/2022 Data fi: 31/10/2027 Investigador/a principal: JOAN BRUNET VIDAL, JOAQUIM BOSCH BARRERA, RAMON BRUGADA TERRADELLAS Organisme finançador: EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HADEA)

Oncología de Precisión de Girona

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Codi oficial: 101095483 Data inicio:01/01/2023 Data fi: 30/06/2026 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HADEA)

Oncología de Precisión de Girona

Y-RNAs AS NON-INVASIVE BIOMARKERS FOR EARLY CANCER DETECTION

Codi oficial: IDEAS246813BRUN Data inicio:01/12/2024 Data fi: 30/11/2026 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER

Oncología de Precisión de Girona

PRISMA-II: Estratificación del riesgo de cáncer de mama/ovario mediante incorporación del polygenic risk score. Validación en portadoras, cohorte prospectiva, y viabilidad de la secuenciación de genoma

Codi oficial: PI23/01047- PRISMA Data inicio:01/01/2024 Data fi: 31/12/2026 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Oncología de Precisión de Girona

Rofes, P, Castillo-Manzano, C, Menéndez, M, Teulé, A, Iglesias, S, Munté, E, Ramos-Muntada, M, Gómez, C, Tornero, E, Darder, E, Montes, E, Valle, L, Capellá, G, Pineda, M, Brunet, J, Feliubadaló, L, del Valle, J, Lázaro, C

<i>TP53</i> germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate

GENOME MEDICINE, 2025, 17, 3-3 dx.doi.org/10.1186/s13073-025-01429-5

Oncología de Precisión de Girona

Peremiquel-Trillas P, Martínez JM, Paytubi S, Frias-Gomez J, Pelegrina B, Marin F, Benavente Y, Ibáñez R, Barahona M, Fernandez-Gonzalez S, Cárdenas L, Taltavull A, Darder E, de Sanjosé S, Widschwendter M, Matias-Guiu X, Bosch X, Pineda M, Ponce J, Brunet J, Alemany L, Costas L

Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.

INTERNATIONAL JOURNAL OF CANCER, 2025, 156, 1791-1801 dx.doi.org/10.1002/ijc.35368

Oncología de Precisión de Girona

López-Fernández A, Duran-Lozano L, Villacampa G, Pardo M, Pérez E, Darder E, Vallmajó A, Alfonso R, Cruellas M, Roqué A, Cartró M, Bareas A, Carrasco E, Rezqallah A, Jimenez-Macedo AR, Torres-Esquius S, Torres M, Lopez C, Espinosa M, Teulé A, Munté E, Tuset N, Diez O, Feliubadaló L, Lázaro C, Llort G, Carver T, Ficorella L, Mavaddat N, Mercadé A, Antoniou AC, Brunet J, Ramon Y Cajal T, Balmaña J

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025 dx.doi.org/10.1093/jnci/djaf067

Oncología de Precisión de Girona

Fernández-Castillejo S, Roig B, Melé M, Serrano S, Salvat M, Querol M, Brunet J, Pineda M, Cisneros A, Parada D, Badia J, Borràs J, Rodríguez-Balada M, Gumà J

Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer

JOURNAL OF MEDICAL GENETICS, 2024, 61, 69-77 dx.doi.org/10.1136/jmg-2023-109389

Oncología de Precisión de Girona

Gonzalez-Abuin N, Pons T, Fuster T, Quintana I, Terradas M, Aiza G, Brunet J, Capellá G, Hampel H, Valle L

Lack of evidence for germline <i>WWP1</i> pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome

GENES & DISEASES, 2024, 11, 524-527 dx.doi.org/10.1016/j.gendis.2023.03.011

Oncología de Precisión de Girona , Epidemiología descriptiva, genética y prevención del cáncer

Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre GM, Fox L, Tondini C, Brunet J, Carmona-García M, Lambertini M, Bower M, Newsom-Davis T, Sharkey R, Pria AD, Rossi M, Plaja A, Salazar R, Sureda A, Prat A, Michalarea V, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rimassa L, Rossi S, Rizzo G, Pedrazzoli P, Lee AJ, Murphy C, Belessiotis K, Diamantis N, Mukherjee U, Pommeret F, Stoclin A, Martinez-Vila C, Bruna R, Gaidano G, D'Avanzo F, Gennari A, Athale J, Eichacker P, Pinato DJ, Torabi-Parizi P, Cortellini A

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 139, 13-20 dx.doi.org/10.1016/j.ijid.2023.11.021

Oncología de Precisión de Girona

Vincenzi B, Cortellini A, Mazzocca A, Orlando S, Romandini D, Aguilar-Company J, Ruiz-Camps I, Valverde Morales C, Eremiev-Eremiev S, Tondini C, Brunet J, Bertulli R, Provenzano S, Bower M, Generali D, Salazar R, Sureda A, Prat A, Vasiliki M, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rossi S, Jackson A, Grosso F, Lee AJX, Murphy C, Belessiotis K, Mukherjee U, Pommeret F, Loizidou A, Gaidano G, Dettorre GM, Grisanti S, Tucci M, Fulgenzi CAM, Gennari A, Napolitano A, Pinato DJ

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16 dx.doi.org/10.1177/17588359231225028

Oncología de Precisión de Girona

Pardo-Cea MA, Farré X, Esteve A, Palade J, Espín R, Mateo F, Alsop E, Alorda M, Blay N, Baiges A, Shabbir A, Comellas F, Gómez A, Arnan M, Teulé A, Salinas M, Berrocal L, Brunet J, Rofes P, Lázaro C, Conesa M, Rojas JJ, Velten L, Fendler W, Smyczynska U, Chowdhury D, Zeng Y, He HH, Li R, Van Keuren-Jensen K, de Cid R, Pujana MA

Biological basis of extensive pleiotropy between blood traits and cancer risk

GENOME MEDICINE, 2024, 16, 21-21 dx.doi.org/10.1186/s13073-024-01294-8

Oncología de Precisión de Girona

Fortuno C, Feng BJ, Carroll C, Innella G, Kohlmann W, Lázaro C, Brunet J, Feliubadaló L, Iglesias S, Menéndez M, Teulé A, Ballinger ML, Thomas DM, Campbell A, Field M, Harris M, Kirk J, Pachter N, Poplawski N, Susman R, Tucker K, Wallis M, Williams R, Cops E, Goldgar D, kConFab Investigators, James PA, Spurdle AB

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.

JCO Precision Oncology, 2024, 8, 2300453-2300453 dx.doi.org/10.1200/PO.23.00453

Oncología de Precisión de Girona

Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

CANCER MEDICINE, 2024, 13 dx.doi.org/10.1002/cam4.7041

12 3 4 5 ›»

Directori

Projectes

Publicacions

<i>TP53</i> germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate

Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.

Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer

Lack of evidence for germline <i>WWP1</i> pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

Biological basis of extensive pleiotropy between blood traits and cancer risk

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Formulari de contacte

Conoce el IDIBGI!